FBRX vs. SLGL, ACST, QLI, DRRX, ITRM, EYEN, LPCN, VAXX, UBX, and SNSE
Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Sol-Gel Technologies (SLGL), Acasti Pharma (ACST), Qilian International Holding Group (QLI), DURECT (DRRX), Iterum Therapeutics (ITRM), Eyenovia (EYEN), Lipocine (LPCN), Vaxxinity (VAXX), Unity Biotechnology (UBX), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical preparations" industry.
Forte Biosciences (NASDAQ:FBRX) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.
77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 10.5% of Forte Biosciences shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Forte Biosciences has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.
Forte Biosciences presently has a consensus target price of $2.75, suggesting a potential upside of 287.32%. Sol-Gel Technologies has a consensus target price of $8.00, suggesting a potential upside of 769.57%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Forte Biosciences.
In the previous week, Forte Biosciences and Forte Biosciences both had 1 articles in the media. Sol-Gel Technologies' average media sentiment score of 0.00 beat Forte Biosciences' score of -0.03 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.
Forte Biosciences has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -1,331.01%. Sol-Gel Technologies' return on equity of -61.52% beat Forte Biosciences' return on equity.
Sol-Gel Technologies has higher revenue and earnings than Forte Biosciences. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
Sol-Gel Technologies received 122 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 63.09% of users gave Sol-Gel Technologies an outperform vote while only 56.82% of users gave Forte Biosciences an outperform vote.
Summary
Sol-Gel Technologies beats Forte Biosciences on 13 of the 16 factors compared between the two stocks.
Get Forte Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Forte Biosciences Competitors List
Related Companies and Tools
